Get started
Author

Guillaume Berton

Intensive induction chemotherapy vs hypomethylating agents in combination with venetoclax in NPM1-mutant AML
2024 · Jan Philipp Bewersdorf, Shai Shimony, et al. · Blood Advances · 13
Combination therapy with hypomethylating agents and venetoclax versus intensive induction chemotherapy in IDH1‐ or IDH2‐mutant newly diagnosed acute myeloid leukemia—A multicenter cohort study
2024 · Jan Philipp Bewersdorf, Shai Shimony, et al. · American Journal of Hematology · 9
PDF
Poor prognosis of SRSF2 gene mutations in patients treated with VEN-AZA for newly diagnosed acute myeloid leukemia
2024 · Guillaume Berton, Bochra Sedaki, et al. · Leukemia Research · 7
Comparative effectiveness of HMA with venetoclax vs intensive chemotherapy in AML with very high-risk cytogenetics
2026 · Luis E. Aguirre, Jan Philipp Bewersdorf, et al. · Blood Neoplasia · 5
Venetoclax-Based Therapy Versus Intensive Chemotherapy Followed By Allogeneic-Stem Cell Transplantation for High-Risk Elderly Acute Myeloid Leukemia
2024 · Alexandre Iat, Jan Philipp Bewersdorf, et al. · Blood · 2
PDF
Outcomes of Elderly Patients Admitted to the Intensive Care Unit for Newly Diagnosed Acute Myeloid Leukemia
2025 · Guillaume Berton, Sylvain Garciaz, et al. · European Journal Of Haematology · 1
PDF
Poor Prognosis of SRSF2 Gene Mutations in Patients Treated with Venetoclax-Azacitidine (VEN-AZA) for Newly Diagnosed Acute Myeloid Leukemia. a Multicentric Real-Life Study of 117 Patients
2023 · Guillaume Berton, Bochra Sedaki, et al. · Blood · 1
PDF
Beyond classical boundaries: rethinking ICU access in acute leukemia
2026 · Guillaume Berton, Norbert Vey · Intensive Care Medicine
PDF
Fludarabine, cyclophosphamide and 2 Gy TBI with PT-Cy as a single platform for haplo and unrelated donor allo-SCT in older AML or MDS patients
2026 · Guillaume Berton, Sabine Fürst, et al. · Bone Marrow Transplantation
Hypomethylating agents plus venetoclax versus intensive chemotherapy prior to transplant in high-risk acute myeloid leukemia
2026 · Guillaume Berton, Jan Philipp Bewersdorf, et al. · Haematologica
PDF
Hypomethylating agents plus venetoclax versus intensive chemotherapy in acute myeloid leukemia with chromosome 5 and 7 abnormalities
2026 · Leora Boussi, Jan Philipp Bewersdorf, et al. · Haematologica
PDF
Impact of CDA Dynamics on Clinical Outcome of Patients With AML or High‐Risk MDS Treated With Nucleoside Analogs
2025 · Erwann Collomb, Laurent Bourguignon, et al. · Hematological Oncology
PDF
Author response for "Impact of CDA Dynamics on Clinical Outcome of Patients With AML or High‐Risk MDS Treated With Nucleoside Analogs"
2025 · Erwann Collomb, Laurent Bourguignon, et al.
Long-term survival of NPM1 AML treated with intensive chemotherapy with extensive molecular data available
2024 · Sylvain Garciaz, Guillaume Berton, et al. · Leukemia & lymphoma/Leukemia and lymphoma
Pb1844: Real: a Retrospective Study of the Clinico-biological Features of Acute Myeloid Leukemia and Myelodysplastic Syndromes Patients Included in an Early Phase Trial at a Comprehensive Cancer Center.
2023 · Guillaume Berton, Cécile Vicier, et al. · HemaSphere
Therapy-related myeloid neoplasms after 177Lu-DOTATATE therapy for metastatic neuroendocrine neoplasia: CPX-351 consolidated by allogeneic stem cells transplantation as applicable therapeutic strategy
2023 · Guillaume Berton, Robin Arcani, et al. · Leukemia & lymphoma/Leukemia and lymphoma
Works count: 17
Citation count: 38
H-index: 4
I10-index: 1
Year
Topic
Type